Effect of Oral Insulin on Early Combined Glucose and C‐Peptide Endpoints in Individuals at High‐Risk for Type 1 Diabetes
Authors' conclusion
These findings support a favorable early effect of OI on combined glucose and C-peptide endpoints in high-risk individuals, indicating metabolic benefit.
Study context
- Population
- Relatives with multiple islet autoantibodies and low first-phase insulin release (high-risk secondary stratum 1)
- Participants
- 40 relatives
- Comparison
- Oral insulin vs placebo
- Primary endpoint
- Change in combined glucose and C-peptide markers: centroid ratio of 30–120-min oral glucose tolerance test (OGTT) glucose and C-peptide on two-dimensional grids
- Follow-up
- 1 year
Methodological detailsplacebo-controlled, Trial participants followed for a median 2.7 years
- Placebo-controlled
- Trial participants followed for a median 2.7 years
Primary result
As reported in the abstract
Change in centroid ratio (combined OGTT glucose and C-peptide) · 1 year
- Glucose rose and C-peptide declined with placebo; glucose rose minimally and C-peptide increased with Oral Insulin (OI)
- Changes in centroid ratio differed between groups
- Between OI and Placebo: P = 0.037
- Post hoc analysis
Original publication
Effect of Oral Insulin on Early Combined Glucose and C‐Peptide Endpoints in Individuals at High‐Risk for Type 1 Diabetes. Pediatr Diabetes. Published 3 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →